Primer Plazma Hücreli Lösemi: Olgu Sunumu
Plazma hücreli lösemi (PHL), plazma hücreli diskrazilerin nadir görülen bir formudur. Primer ve sekonder PHL olmak üzere iki formu vardır. Prognozu oldukça kötüdür. Morfolojik olarak matür plazma hücrelerine benzememesi sebebiyle tanıda karışıklıklar olabilmektedir. Tedavide bortezomib bazlı rejimler ve otolog kök hücre nakli önerilmektedir.
Primary Plasma Cell Leukemia: Case Report
Plasma cell leukemia (PHL) is a rare form of plasma cell dyscrasias. There are two forms of primary and secondary PHL. The prognosis is very poor. Since the morphology does not resemble mature plasma cells, there may be confusion in the diagnosis. Bortezomib based regimens and autologous stem cell transplantation are recommended for treatment.
___
- 1. Sant M, Allemani C, Tereanu C, et all. Incidence of
hematologic malignancies in Europe by morphologic
subtype: results of the HAEMACARE project. Blood
2010; 116: 3724-34.
- 2. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of
response to therapy. The American journal of medicine
1987; 83: 1062-8.
- 3. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et all. Genetic
aberrations and survival in plasma cell leukemia.
Leukemia 2008; 22: 1044-52.
- 4. Fernandez de Larrea C, Kyle RA, Durie BG, et all.
Plasma cell leukemia: consensus statement on
diagnostic requirements, response criteria and
treatment recommendations by the International
Myeloma Working Group. Leukemia 2013; 27: 780-91.
- 5. Garcia-Sanz R, Orfao A, Gonzalez M, et all. Primary
plasma cell leukemia: clinical, immunophenotypic, DNA
ploidy, and cytogenetic characteristics. Blood 1999; 93:
1032-7.
- 6. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM.
Multiple myeloma: significance of plasmablastic
subtype in morphological classification. Blood 1985;
65: 305-10.
- 7. Kyle RA, Gertz MA, Witzig TE, et all. Review of 1027
patients with newly diagnosed multiple myeloma.
Mayo Clin Proc 2003; 78: 21-33.
- 8. Blade J, Kyle RA. Multiple myeloma in young patients:
clinical presentation and treatment approach. Leuk
Lymphoma 1998; 30: 493-501.
- 9. Gonsalves WI, Rajkumar SV, Go RS, et all. Trends in
survival of patients with primary plasma cell leukemia:
a population-based analysis. Blood 2014; 124: 907-12.
- 10. Musto P. Progress in the Treatment of Primary
Plasma Cell Leukemia. Journal of clinical oncology:
official journal of the American Society of Clinical
Oncology 2016; 34: 2082-4.
- 11. Musto P, Simeon V, Martorelli MC, et all.
Lenalidomide and low-dose dexamethasone for newly
diagnosed primary plasma cell leukemia. Leukemia
2014; 28: 222-5.
- 12. Royer B, Minvielle S, Diouf M, et all. Bortezomib,
Doxorubicin, Cyclophosphamide, Dexamethasone
Induction Followed by Stem Cell Transplantation for
Primary Plasma Cell Leukemia: A Prospective Phase II
Study of the Intergroupe Francophone du Myelome.
Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2016; 34: 2125-
32.
- 13. Jung SH, Lee JJ, Kim K, et all. The role of frontline
autologous stem cell transplantation for primary
plasma cell leukemia: a retrospective multicenter study
(KMM160). Oncotarget 2017; 8: 79517-26.
- 14. Granell M, Calvo X, Garcia-Guinon A, et all. Prognostic
impact of circulating plasma cells in patients with
multiple myeloma: implications for plasma cell
leukemia definition. Haematologica 2017; 102: 1099-
104.
- 15. D'Arena G, Valentini CG, Pietrantuono G, et all.
Frontline chemotherapy with bortezomib-containing
combinations improves response rate and survival in
primary plasma cell leukemia: a retrospective study
from GIMEMA Multiple Myeloma Working Party. Ann
Oncol 2012; 23: 1499-502.
- 16. Katodritou E, Terpos E, Kelaidi C, et all. Treatment
with bortezomib-based regimens improves overall
response and predicts for survival in patients with
primary or secondary plasma cell leukemia: Analysis of
the Greek myeloma study group. American journal of
hematology 2014; 89: 145-50.
- 17. Lebovic D, Zhang L, Alsina M, et all. Clinical outcomes
of patients with plasma cell leukemia in the era of novel
therapies and hematopoietic stem cell transplantation
strategies: a single-institution experience. Clinical
lymphoma, myeloma & leukemia 2011; 11: 507-11.
- 18. van de Donk NW, Lokhorst HM, Anderson KC,
Richardson PG. How I treat plasma cell leukemia. Blood
2012; 120: 2376-89.
- 19. Mahindra A, Kalaycio ME, Vela-Ojeda J, et all.
Hematopoietic cell transplantation for primary plasma
cell leukemia: results from the Center for International
Blood and Marrow Transplant Research. Leukemia
2012; 26: 1091-7.
- 20. Nishihori T, Abu Kar SM, Baz R, et all. Therapeutic
advances in the treatment of primary plasma cell
leukemia: a focus on hematopoietic cell
transplantation. Biology of blood and marrow
transplantation : journal of the American Society for
Blood and Marrow Transplantation 2013; 19: 1144-51.
- 21. Chim CS, Kumar SK, Orlowski RZ, et all. Management
of relapsed and refractory multiple myeloma: novel
agents, antibodies, immunotherapies and beyond.
Leukemia 2018; 32: 252-62.